Glossary of EBM Terms

[ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z ]

A
Absolute risk reduction (ARR)
See treatment effects.

Allocation concealment
Occurs when the person who is enrolling a participant into a clinical trial is unaware
whether the next participant to be enrolled will be allocated to the intervention or control
group.

- back to top -

C
Case-control study
A study which involves identifying patients who have the outcome of interest (cases)
and patients without the same outcome (controls), and looking back to see if they had the
exposure of interest.

Case series
A report on a series of patients with an outcome of interest. No control group is involved.

Clinical Practice Guideline

A systematically developed statement designed to assist clinician and patient decisions
about appropriate health care for specific clinical circumstances.

Cohort Study
Involves identification of two groups (cohorts) of patients, one which received the
exposure of interest, and one which did not, and following these cohorts forward for the
outcome of interest.

Confidence Interval (CI)

Quantifies the uncertainty in measurement. It is usually reported as a 95% CI which is
the range of values within which we can be 95% sure that the true value for the whole
population lies. For example, for an NNT of 10 with a 95% CI of 5 to 15, we would have
95% confidence that the true NNT value lies between 5 and 15.

Control Event Rate (CER)

See treatment effects.
 Cost-benefit analysis
Assesses whether the cost of an intervention is worth the benefit by measuring both in
the same units; monetary units are usually used.

Cost-effectiveness analysis
Measures the net cost of providing an intervention as well as the outcomes obtained.
Outcomes are reported in a single unit of measurement.

Cost-minimization analysis
If health effects are known to be equal, only costs are analyzed and the least costly
alternative is chosen.

Cost-utility analysis
Converts health effects into personal preferences (or utilities) and describes how much it
costs for some additional quality gain (e.g. cost per additional quality-adjusted life-year,
or QALY).

Crossover study design

The administration of two or more experimental therapies one after the other in a
specified or random order to the same group of patients.

Cross-sectional study
The observation of a defined population at a single point in time or time interval.
Exposure and outcome are determined simultaneously.

- back to top -

D
Decision analysis (or clinical decision analysis)
The application of explicit, quantitative methods that quantify prognoses, treatment
effects, and patient values in order to analyze a decision under conditions of uncertainty.

- back to top -

E
Ecological survey
A survey based on aggregate data for some population as it exists at some point or points
in time; to investigate the relationship of an exposure to a known or presumed risk factor
for a specified outcome.

Event rate
The proportion of patients in a group in whom the event is observed. Thus, if out of 100
patients, the event is observed in 27, the event rate is 0.27. Control event rate (CER) and
experimental event rate (EER) are used to refer to this in control and experimental
groups of patients, respectively. The patient expected event rate (PEER) refers to the rate
of events we'd expect in a patient who received no treatment or conventional treatment.

See treatment effects.

Evidence-based health care

Extends the application of the principles of evidence-based medicine to all professions
associated with health care, including purchasing and management.

Evidence-based medicine (EBM)

The conscientious, explicit and judicious use of current best evidence in making decisions
about the care of individual patients. The practice of evidence-based medicine requires
the integration of individual clinical expertise with the best available external clinical
evidence from systematic research and our patient's unique values and circumstances.

Experimental event rate (EER)

The proportion of patients in the experimental treatment group who are observed to
experience the outcome of interest.

See treatment effects.

- back to top -

H
Heterogeneity
This occurs when there is more variation between the study results (in a systematic
review) than would be expected to occur by chance alone.

- back to top -

I
Incidence
The proportion of new cases of the target disorder in the population at risk during a
specified time interval.

Inception cohort
A group of patients who are assembled near the onset of the target disorder.

Intention-to-treat analysis
A method of analysis for randomized trials in which all patients randomly assigned to
one of the treatments are analyzed together, regardless of whether or not they completed
or received that treatment, in order to preserve randomization.

- back to top -

L
Likelihood ratio (LR)
The likelihood that a given test result would be expected in a patient with the target
disorder compared with the likelihood that this same result would be expected in a
patient without the target disorder.

More details on LR

- back to top -

M
Meta-analysis
A systematic review that uses quantitative methods to synthesize and summarize the
results.

- back to top -

N
N-of-1 trials
In such trials, the patient undergoes pairs of treatment periods organized so that one
period involves the use of the experimental treatment and the other involves the use of
an alternate or placebo therapy. The patient and physician are blinded, if possible, and
outcomes are monitored. Treatment periods are replicated until the clinician and patient
are convinced that the treatments are definitely different or definitely not different.

Negative
predictive value
Proportion of people with a negative test who are free of the target disorder.

See likelihood ratio.

Number
needed to
treat (NNT)
The inverse of the absolute risk reduction and the number of patients that need to be
treated to prevent one bad outcome. Calculated as the inverse of the absolute risk
reduction (1/ARR).
See more details on NNT

See treatment effects.

- back
to
top -

O
Odds
A ratio of the number of people incurring an event to the number of people who don't
have an event.

Od
ds
rati
o
(O
R)
The ratio of the odds of having the target disorder in the experimental group relative to
the odds in favour of having the target disorder in the control group (in cohort studies or
systematic reviews) or the odds in favour of being exposed in subjects with the target
disorder divided by the odds in favour of being exposed in control subjects (without the
target disorder).

See how OR/RR are calculated

O
v
e
r
v
i
e
w
See systematic review.

- ba
ck
to
top 
-

P
 Pati
ent
exp
ecte
d
eve
nt
rate
See treatment effects.

Positi
ve
predic
tive
value
Proportion of people with a positive test who have the target disorder.

See likelihood ratio.

Post-test
odds
The odds that the patient has the target disorder after the test is carried out (calculated as
the pre-test odds x likelihood ratio).

Post-test
probability
The proportion of patients with that particular test result who have the target disorder
(post-test odds/[1 + post-test odds]).

Pre-test odds
The odds that the patient has the target disorder before the test is carried out (pre-test
probability/ [1 - pre-test probability]).

Pre-test
probability
(prevalence)
The proportion of people with the target disorder in the population at risk at a specific
time (point prevalence) or time interval (period prevalence).

See likelihood ratio.

- back to to

R
 Randomization
random allocati
Method analogous to tossing a coin to assign patients to treatment groups (the
experimental treatment is assigned if the coin lands "heads" and a conventional, "control"
or "placebo" treatment is given if the coin lands "tails").

Randomized co
clinical trial (RC
Participants are randomly allocated into an experimental group or a control group and
followed over time for the variables/outcomes of interest.

Relative risk red

(RRR)
See treatment effects.

Risk Ratio
The ratio of risk in the treated group (EER) to the risk in the control group (CER). This is
used in randomized trials and cohort studies and is calculated as EER/CER. Also called
relative risk.

- back

S
Sensitivity
Proportion of people with the target disorder who have a positive test result. It is used to
assist in assessing and selecting a diagnostic test/sign/symptom.

See more details on sensitivity and specificity

See likelihood ratio.

SnNout
When a sign/test/symptom has a high Sensitivity, a Negative result can help rule out the
diagnosis. For example, the sensitivity of a history of ankle swelling for diagnosing
ascites is 93%; therefore if a person does not have a history of ankle swelling, it is highly
unlikely that the person has ascites.

Specificity
Proportion of people without the target disorder who have a negative test. It is used to
assist in assessing and selecting a diagnostic test/sign/symptom.

See more details on sensitivity and specificity

See how specificity is calculated

See likelihood ratio.

 SpPin
What a sign/test/symptom has a high Specificity, a Positive result rules in the diagnosis.
For example, the specificity of a fluid wave for diagnosing ascites is 92%; therefore if a
person does have a fluid wave, it rules in the diagnosis of ascites.

Systematic revi
A summary of the medical literature that uses explicit methods to perform a
comprehensive literature search and critical appraisal of individual studies and that uses
appropriate statistical techniques to combine these valid studies.

T
Treatment effec
The evidence-based journals (Evidence Based Medicine and ACP Journal Club) have
achieved consensus on some terms they use to describe both the good and bad effects of
therapy. We will bring them to life with a synthesis of three randomized trials in diabetes
which individually showed that several years of intensive insulin therapy reduced the
proportion of patients with worsening retinopathy to 13% from 38%, raised the
proportion of patients with satisfactory hemoglobin A1c levels to 60% from about 30%,
and increased the proportion of patients with at least one episode of symptomatic
hypoglycemia to 57% from 23%. Note that in each case the first number constitutes the
"experimental event rate" (EER) and the second number the "control event rate" (CER).
We will use the following terms and calculations to describe these effects of treatment:
When the experimental treatment reduces the probability of a bad outcome (worsening
diabetic retinopathy)

RRR (relative risk reduction)

The proportional reduction in rates of bad outcomes between experimental and control
participants in a trial, calculated as |EER - CER|/CER, and accompanied by a 95%
confidence interval (CI). In the case of worsening diabetic retinopathy, |EER - CER|/CER
= |13% - 38%|/38% = 66%.

ARR (absolute risk reduction)

The absolute arithmetic difference in rates of bad outcomes between experimental and
control participants in a trial, calculated as |EER - CER|, and accompanied by a 95% CI.
In this case, |EER - CER| = |13% - 38%| = 25%. (This is sometimes called the risk
difference)

NNT (number needed to treat)

The number of patients who need to be treated to achieve one additional favorable
outcome, calculated as 1/ARR and accompanied by a 95% CI. In this case, 1/ARR = 1/25%
= 4.
 When the experimental treatment increases the probability of a good outcome
(satisfactory hemoglobin A1c levels):

RBI (relative benefit increase)

The proportional increase in rates of good outcomes between experimental and control
patients in a trial, calculated as |EER - CER|/CER, and accompanied by a 95% confidence
interval (CI). In the case of satisfactory hemoglobin A1c levels, |EER - CER|/CER = |60%
- 30%|/30% = 100%.

ABI (absolute benefit increase)

The absolute arithmetic difference in rates of good outcomes between experimental and
control patients in a trial, calculated as |EER - CER|, and accompanied by a 95%
confidence interval (CI). In the case of satisfactory hemoglobin A1c levels, |EER - CER| =
|60% - 30%| =30%

NNT (number needed to treat)

The number of patients who need to be treated to achieve one additional good outcome,
calculated as 1/ARR and accompanied by a 95% CI. In this case, 1/ARR = 1/30% = 3.

When the experimental treatment increase the probability of a bad

outcome (episodes of hypoglycemia):

RRI (relative risk increase)

The proportional increase in rates of bad outcomes between experimental and control
patients in a trial, calculated as |EER - CER|/CER, and accompanied by a 95% confidence
interval (CI). In the case of hypoglycemic episodes, |EER - CER|/CER = |57% - 23%|/23%
= 148%. (RRI is also used in assessing the impact of "risk factors" for disease.)

ARI (absolute risk increase)

The absolute arithmetic difference in rates of bad outcomes between experimental and
control patients in a trial, calculated as |EER - CER|, and accompanied by a 95%
confidence interval (CI). In the case of hypoglycemic episodes, |EER - CER| = |57% -
23%| = 34%. (ARI is also used in assessing the impact of "risk factors" for disease.)

NNH (number needed to harm)

The number of patients who, if they received the experimental treatment, would result in
one additional patient being harmed, compared with patients who received the control
treatment, calculated as 1/ARI and accompanied by a 95% CI. In this case, 1/ARI = 1/34%
= 3.